Efficacy and safety of inhaled antibiotics for chronic pseudomonas infection in cystic fibrosis: Network meta-analysis

Stuart Elborn (Belfast, United Kingdom), Stuart Elborn, Anne-Lise Vataire, Ayako Fukushima, Samuel Aballéa, Amine Khemiri, Curtis Moore, Goran Medic, Michiel Hemels

Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Session: Cystic fibrosis: inflammation, microbiology, management and monitoring
Session type: Poster Discussion
Number: 4863
Disease area: Paediatric lung diseases, Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Stuart Elborn (Belfast, United Kingdom), Stuart Elborn, Anne-Lise Vataire, Ayako Fukushima, Samuel Aballéa, Amine Khemiri, Curtis Moore, Goran Medic, Michiel Hemels. Efficacy and safety of inhaled antibiotics for chronic pseudomonas infection in cystic fibrosis: Network meta-analysis. Eur Respir J 2016; 48: Suppl. 60, 4863

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Interim data from a long-term safety, tolerability, and efficacy study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonas aeruginosa infection
Source: International Congress 2014 – Cystic fibrosis: assessment and treatment
Year: 2014


Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection
Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Year: 2016


Safety, tolerability and efficacy of intravenous aminophylline in adult patients with pulmonary exacerbations of cystic fibrosis
Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects
Year: 2014

Effectiveness of inhaled colistin by iNeb® device in non-CF bronchiectasis and chronic pseudomonas infection
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation
Year: 2015


Patients with no cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa: Role of inhaled colistin
Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections
Year: 2014


Alternating inhaled antibiotic therapy in CF: A single center analysis
Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment
Year: 2015


Early eradication of pseudomonas aeruginosa (PA) in cystic fibrosis patients (CF): Which is the best treatment?
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children
Year: 2013


LATE-BREAKING ABSTRACT: Is there a relationship between use of inhaled antibiotics and prevalence of fungal isolates in the respiratory secretions of people with cystic fibrosis? A retrospective data analysis
Source: International Congress 2015 – Cystic fibrosis: assessment and treatment
Year: 2015



Lung deposition of inhaled colistimethate sodium in cystic fibrosis patients
Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects
Year: 2014

Prolonged antibiotics for non-cystic fibrosis purulent bronchiectasis in children and adults: A Cochrane review
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014


Role of stenotrophomonas maltophilia infection in CF pulmonary exacerbations
Source: Annual Congress 2013 –Difficult and rare respiratory infections
Year: 2013


The use of telehealth system in improving adherence to nebulised treatment in children with cystic fibrosis: Benefits and pitfalls
Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects
Year: 2014


The characteristics of the minimum inhibitory concentration of antibiotics on pulmonary infections in patients with cystic fibrosis
Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Year: 2015


Influence of severity on outcome in a phase II trial of ciprofloxacin DPI in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients
Year: 2013

Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients
Year: 2013


Emerging pathogens in cystic fibrosis
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=66
Year: 2006

Frequency and pathogenicity of rhinovirus associated pulmonary exacerbations in patients with cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children
Year: 2013

The oral AntibioticS approprIateness score (OASIS) – A novel scoring system to assess antibiotic route in pulmonary exacerbations of cystic fibrosis (CF)
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Year: 2013


The efficacity of omaluzimab in a case series with allergic bronchopulmonary aspergillosis and cystic fibrosis
Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment
Year: 2015


Adaptation of prevotella during acute infectious pulmonary exacerbation
Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology
Year: 2014